MedTrace Logo

Adjunctive Therapy of Andrographolid Sulfonatein Community Acquired Pneumonia

NCT02913118 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 462

Last updated 2018-04-10

No results posted yet for this study

Summary

Adjunctive Therapy of AndrographolidSulfonate in Community Acquired Pneumonia: A Multicenter, Randomized,Double-blinded, Placebo Controlled Clinical Trial. The hypothesis is that combination therapy with Andrographolid Sulfonatein injection and antibacterial is significantly better than antibacterial alone in achieving clinical stability among hospitalized CAP patients.

Conditions

  • Community Acquired Pneumonia

Interventions

DRUG

Andrographolid Sulfonate Injection (AS Injection)

DRUG

Cephalosporin

DRUG

Azithromycin, Minocycline or Doxycycline

DRUG

Amoxicillin-clavulantic acid

DRUG

Fluoroquinolones

DRUG

Placebo

Sponsors & Collaborators

  • Qingfeng Pharmaceutical Group

    lead INDUSTRY

Principal Investigators

  • Chen Wang, Professor · China-Japan Friendship Hospital

  • Bin Cao, Professor · China-Japan Friendship Hospital

  • Jin Chen, Professor · Fu Xing Hospital, Capital Medical University

  • Yuguang Wang, Professor · Beijing Hospital of TCM

  • Li Gu, Professor · Beijing Chao Yang Hospital

  • Zhenyang Xu, Professor · Capital Medical University

  • Yan Yi, Professor · First Hospital of China Medical University

  • Wei Zhang, Professor · The First Affiliated Hospital of Nanchang University

  • Shufeng Xu, Professor · First Hospital of Qinhuangdao

  • Bo Liu, Professor · The Central Hospital of ZiBo City

  • Jie Cao, Professor · Tianjin Medical University General Hospital

  • Yuping Li, Professor · The First Affiliated Hospital of Wenzhou University

  • Xuedong Liu, Professor · Qingdao Municipal Hospital

  • Hong Fan, Professor · West China Hospital

  • Zhigang Cai, Professor · The Second Hospital of Hebei Medical University

  • Xinri Zhang, Professor · The First Affiliated Hospital of Shanxi Medical University

  • Xin Su, Professor · Nanjing General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2019-01-31
Completion
2019-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02913118 on ClinicalTrials.gov